Document is current

Article History

Received: 8 September 2025

Accepted: 10 October 2025

First Online: 15 November 2025

Declarations

:

: Marc-Oliver Grimm received research grants from Bayer Health Care, Bristol Myers Squibb, and Intuitive Surgical; received honoraria from Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, Ipsen, Janssen Cilag, Merck, MSD, Novatis, and Telix; participated on Data Safety Monitoring or Advisory Boards for Astellas, Astra Zeneca, Bayer Health Care, Bristol Myers Squibb, Eisai, Gilead, Ipsen, Janssen Cilag, Kranus, Merck Serono, MSD, Novartis, Pfizer Pharma, Recordati, Roche Pharma, and Telix. Emma Karim, Mickael Lothgren, and Alessia Ogareva are employees of Ipsen. Venediktos Kapetanakis, Pragya Shukla, and James Truscott are employees of Evidera, which was contracted by Ipsen to conduct the data analysis. Camillo Porta acted as a remunerated consultant or speaker for Angelini Pharma, AstraZeneca, BMS, Eisai, Exelixis, Genenta, GenMab, Ipsen, Merck Serono, and MSD; as a Protocol Steering Committee member for Eisai and MSD; and as a Protocol Safety Monitoring Board member for Genenta.

: The results presented in this manuscript are based on data from the published CheckMate 9ER trial. All procedures were conducted in accordance with Good Clinical Practice guidelines defined by the International Council for Harmonisation. Enrolled patients provided written informed consent according to the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the original trial. International review board number 930112125. The results presented in this manuscript are based on published studies. Informed consent was obtained from all individual participants included in the CheckMate 9ER trial (ClinicalTrials.gov identifier NCT03141177).